XML 53 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue Recognition and Collaborative Arrangements (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK $ 65,755 $ 61,680 $ 185,045 $ 181,146
GSK        
Revenue Recognition and Collaborative Arrangements        
Total net revenue from GSK 65,755 61,680 185,045 181,146
GSK | Royalty revenue from a related party        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 69,211 65,136 195,413 191,514
Less: amortization of capitalized fees paid to a related party (3,456) (3,456) (10,368) (10,368)
GSK | RELVAR/BREO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 46,433 51,745 136,259 155,420
GSK | ANORO        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party 11,548 9,769 30,753 29,149
GSK | TRELEGY        
Revenue Recognition and Collaborative Arrangements        
Royalties from a related party $ 11,230 $ 3,622 $ 28,401 $ 6,945